S
VIRX

SignatureFD’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

SignatureFD’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2
Closed – – 2698
2020
Q1 		$0 Hold
2
– – ﹤0.01% 2492
2019
Q4 		$0 Hold
2
– – ﹤0.01% 2302
2019
Q3 		$0 Hold
2
– – ﹤0.01% 2222
2019
Q2 		$0 Hold
2
– – ﹤0.01% 2180
2019
Q1 		$0 Hold
2
– – ﹤0.01% 2075
2018
Q4 		$0 Hold
2
– – ﹤0.01% 2093
2018
Q3 		$0 Hold
2
– – ﹤0.01% 2021
2018
Q2 		$0 Hold
2
– – ﹤0.01% 1988
2018
Q1 		$0 Buy
+2
New +$343 ﹤0.01% 1775
2016
Q4 		– Sell
-2
Closed – – 1286
2016
Q3 		$0 Hold
2
– – ﹤0.01% 1658
2016
Q2 		$0 Hold
2
– – ﹤0.01% 1537
2016
Q1 		$0 Hold
2
– – ﹤0.01% 1464
2015
Q4 		$0 Hold
2
– – ﹤0.01% 1384
2015
Q3 		$0 Hold
2
– – ﹤0.01% 1387
2015
Q2 		$1K Hold
2
– – ﹤0.01% 1015
2015
Q1 		$1K Hold
2
– – ﹤0.01% 916
2014
Q4 		$1K Buy
+2
New +$901 ﹤0.01% 825

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SignatureFD's VIRX Position: Q2 2020 in Review

SignatureFD sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2020, closing a stake of 2 shares.

SignatureFD first reported a position in VIRX in Q4 2014 and held it in 17 quarters. The position peaked at $1K in Q2 2015. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2020.

  • SignatureFD reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • SignatureFD sold 2 Viracta Therapeutics, Inc. Common Stock shares in Q2 2020.
  • SignatureFD first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2014 and held it in 17 quarters.
  • SignatureFD's Viracta Therapeutics, Inc. Common Stock position peaked at $1K in Q2 2015.
  • 41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2020.

Based on SignatureFD's 13F filing for Q2 2020, filed 30 Jul 2020.